



PATENT
Attorney Docket No. **UM-08196**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **David G. Beer *et al.***
Serial No.: **10/617,067**
Filed: **07/10/03**
Entitled: **Expression Profile of Lung Cancer**

Group No.: **1643**
Examiner: **Sang**

**INFORMATION DISCLOSURE
STATEMENT TRANSMITTAL**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on January 31, 2007.

By: 

Mary Ellen Waite


Sir or Madam:

Enclosed please find an Information Disclosure Statement and Form PTO-1449, including copies of the references contained thereon, for filing in the U.S. Patent and Trademark Office.

A check for \$180.00 is also enclosed pursuant to 37 C.F.R. § 1.17(p) for filing this Information Disclosure Statement after three months as set forth in C.F.R. § 1.97(c).

The Commissioner is hereby authorized to charge any additional fee or credit overpayment to our Deposit Account No. 08-1290. An originally executed duplicate of this transmittal is enclosed for this purpose.

Dated: January 31, 2007


Tanya A. Arenson
Registration No. 47,391

02/05/2007 AWONDAF1 00000074 10617067

01 FC:1806

180.00 0P

MEDLEN & CARROLL, LLP
101 Howard Street, Suite 305
San Francisco, California 94105
608/218-6900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **David G. Beer *et al.***
Serial No.: **10/617,067**
Filed: **07/10/03**
Entitled: **Expression Profile of Lung Cancer**

Group No.: **1643**
Examiner: **Sang**

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: January 31, 2007

By: _____

M. E. Waite
Mary Ellen Waite

Sir or Madam:

The citations listed below may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.

- Gail et al., "Prognostic factors in patients with resected stage I non-small cell lung cancer. A report from the Lung Cancer Study Group," *Cancer* 54:1802 1984]
- Takise et al., "Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 cm in diameter," *Cancer* 61:2083 [1988]
- Ichinose et al., "Is T factor of the TNM staging system a predominant prognostic factor in pathologic stage I non-small-cell lung cancer ? A multivariate prognostic factor analysis of 151 patients," *J. Thorac. Cardiovasc. Surg.* 106:90 [1993]

- Harpole et al., "A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression," *Cancer Res.* 55(1):51-5 [1995]
- Rodenhuis et al., "Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung," *N. Engl. J. Med.* 317:929 [1987]
- Slebos et al., "K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung," *N. Engl. J. Med.* 323:561 [1990]
- Horio et al., "Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer," *Cancer Res.* 53:1 [1993]
- Stieber et al., "Tumour markers in lung cancer: EGTm recommendations," *Anticancer Research*, 19:2817 [1999]
- Schneider et al., "Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer," *Br. J. Cancer*, 83:473 [2000]
- Alaiya et al., "Cancer proteomics: from identification of novel markers to creation of artificial learning models for tumor classification," *Electrophoresis* 21:1210 [2000]
- Kansra et al., "IGFBP-3 mediates TGF beta 1 proliferative response in colon cancer cells," *Int. J. Cancer* 87:373 [2000]
- Vadgama et al., "Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women," *Oncology* 57:330 [1999]
- Golub et al., "Molecular classification of cancer: class discovery and class prediction by gene expression monitoring," *Science* 286 531 [1999]
- Hedenfalk et al., "Gene-expression profiles in hereditary breast cancer," *N. Engl. J. Med.* 344:539 [2001]
- Ohta et al., "Vascular endothelial growth factor and lymph node metastasis in primary lung cancer," *Br. J. Cancer* 76:1041 [1997]

- Shibusa et al., "Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma," Clin. Cancer Res. 4:1483 [1998]
- Girardin et al., "A direct interaction between JNK1 and CrkII is critical for Rac1-induced JNK activation," EMBO J. 20:3437 [2001]
- Wu, "Review of circulating tumor markers: from enzyme, carcinoembryonic protein to oncogene and suppressor gene," Annals of Clinical and Laboratory Science, 29:106 [1999]
- Schwartz, "Enzyme patterns in cancer," Annals of Clinical and Laboratory Science, 7:99 [1977]
- Stefanini, "Enzymes, isozymes, and enzyme variants in the diagnosis of cancer. A short review," Cancer, 55:1931 [1985]
- Hibi et al., "PGP9.5 as a candidate tumor marker for non-small-cell lung cancer," Am. J. Pathol., 155:711 [1999]
- Brichory et al., "Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer," Cancer Res., 61:7908 [2001]
- Koivunen et al., "Structures of the human gene for the protein disulfide isomerase-related polypeptide ERp60 and a processed gene and assignment of these genes to 15q15 and 1q21," Genomics, 42:397 [1997]
- Hirano et al., "Molecular cloning of the human glucose-regulated protein ERp57/GRP58, a thiol-dependent reductase. Identification of its secretory form and inducible expression by the oncogenic transformation," Eur. J. Biochem., 234:336 [1995]
- Montgomerie et al., "The 28K protein in urinary bladder, squamous metaplasia and urine is triosephosphate isomerase," Clin. Biochem., 30:613 [1997]
- Tew et al., "Glutathione-associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program," Mol. Pharmacol. 50:149 [1996]


- Nakamura et al., "Dynamics of bovine glial fibrillary acidic protein phosphorylation," *Neurosci Lett* 205:91 [1996]
- Giasson et al., "Intermediate filament disassembly in cultured dorsal root ganglion neurons is associated with amino-terminal head domain phosphorylation of specific subunits," *J Neurochem* 70: 1869 [1998]
- Escribano and Rozengurt, "Cyclic AMP increasing agents rapidly stimulate vimentin phosphorylation in quiescent cultures of Swiss 3T3 cells," *J Cell Physiol* 137: 223 [1988]
- Eriksson et al., "Cytoskeletal integrity in interphase cells requires protein phosphatase activity," *Proc Natl Acad Sci USA* 89:11093 [1992]
- Ku et al., "Identification of the major physiologic phosphorylation site of human keratin 18: potential kinases and a role in filament reorganization," *J Cell Biol.* 127:161 [1994]
- MacFarlane et al., "Active caspases and cleaved cytokeratins are sequestered into cytoplasmic inclusions in TRAIL-induced apoptosis," *J Cell Biol* 148:1239 [2000]
- Leers et al., "Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis," *J Pathol.* 187:567 [1999]
- Spencer et al., "Estrogen regulates the association of intermediate filament proteins with nuclear DNA in human breast cancer cells," *J Biol Chem* 273:29093 [1998]
- Hembrough et al., "Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation," *Biochem J* 317:763 [1996]
- Fujita et al., "Detection of large molecular weight cytokeratin 8 as carrier protein of CA19-9 in non-small-cell lung cancer cell lines," *Br J Cancer* 81:769 [1999]
- Takada et al., "Adhesion of human cancer cells to vascular endothelium mediated by a carbohydrate antigen, sialyl Lewis A.," *Biochem Biophys Res Commun* 179:713 [1991]

- Takada et al., "Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium.," *Cancer Res* 53:354 [1993]
- Pujol et al., "Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer," *Cancer Res* 53:61 [1993]
- Pujol et al., "Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS," *Am J Respir Crit Care Med* 154:725 [1996]
- Giordano et al., "Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles," *Am. J. Pathol.* 159:1231 [2001]
- Hanash et al., "Data base analysis of protein expression patterns during T-cell ontogeny and activation," *PNAS* 90:3314 [1993]
- Oh et al., "A database of protein expression in lung cancer," *Proteomics* 1:1303 [2001]
- Moll et al., "The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells," *Cell* 31:11 [1982]
- Glass et al., "Isolation, sequence, and differential expression of a human K7 gene in simple epithelial cells," *J Cell Biol* 107:1337 [1988]
- Leube et al., "Cytokeratin expression in simple epithelia. III. Detection of mRNAs encoding human cytokeratins nos. 8 and 18 in normal and tumor cells by hybridization with cDNA sequences in vitro and in situ," *Differentiation* 33:69-85 [1986]
- Broers et al., "Expression of intermediate filament proteins in fetal and adult human lung tissues," *Differentiation* 40:119 [1989]

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Dated: _____

1/31/07



Tanya A. Arenson
Registration No. 47,391
MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
608/218-6900



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/617,067
		Filing Date	7/10/2003
		First Named Inventor	Beer et al.
		Art Unit	1643
		Examiner Name	Sang
Sheet 1	of 5	Attorney Docket Number	UM-08196

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Gail et al., "Prognostic factors in patients with resected stage I non-small cell lung cancer. A report from the Lung Cancer Study Group," Cancer 54:1802 [1984]	
	2	Takise et al., "Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 cm in diameter," Cancer 61:2083 [1988]	
	3	Ichinose et al., "Is T factor of the TNM staging system a predominant prognostic factor in pathologic stage I non-small-cell lung cancer? A multivariate prognostic factor analysis of 151 patients," J. Thorac. Cardiovasc. Surg. 106:90 [1993]	
	4	Harpole et al., "A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression," Cancer Res. 55(1):51-5 [1995]	
	5	Rodenhuis et al., "Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung," N. Engl. J. Med. 317:929 [1987]	
	6	Slebos et al., "K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung," N. Engl. J. Med. 323:561 [1990]	
	7	Horio et al., "Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer," Cancer Res. 53:1 [1993]	
	8	Stieber et al., "Tumour markers in lung cancer: EGTM recommendations," Anticancer Research, 19:2817 [1999]	
	9	Schneider et al., "Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer," Br. J. Cancer, 83:473 [2000]	
	10	Alaiya et al., "Cancer proteomics: from identification of novel markers to creation of artificial learning models for tumor classification," Electrophoresis 21:1210 [2000]	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/617,067
		Filing Date	7/10/2003
		First Named Inventor	Beer et al.
		Art Unit	1643
		Examiner Name	Sang
Sheet 2 of 5	Attorney Docket Number	UM-08196	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	11	Kansra et al., "IGFBP-3 mediates TGF beta 1 proliferative response in colon cancer cells," Int. J. Cancer 87:373 [2000]	
	12	Vadgama et al., "Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women," Oncology 57:330 [1999]	
	13	Golub et al., "Molecular classification of cancer: class discovery and class prediction by gene expression monitoring," Science 286 531 [1999]	
	14	Hedenfalk et al., "Gene-expression profiles in hereditary breast cancer," N. Engl. J. Med. 344:539 [2001]	
	15	Ohta et al., "Vascular endothelial growth factor and lymph node metastasis in primary lung cancer," Br. J. Cancer 76:1041 [1997]	
	16	Shibusa et al., "Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma," Clin. Cancer Res. 4:1483 [1998]	
	17	Girardin et al., "A direct interaction between JNK1 and CrkII is critical for Rac1-induced JNK activation," EMBO J. 20:3437 [2001]	
	18	Wu, "Review of circulating tumor markers: from enzyme, carcinoembryonic protein to oncogene and suppressor gene," Annals of Clinical and Laboratory Science, 29:106 [1999]	
	19	Schwartz, "Enzyme patterns in cancer," Annals of Clinical and Laboratory Science, 7:99 [1977]	
	20	Stefanini, "Enzymes, isozymes, and enzyme variants in the diagnosis of cancer. A short review," Cancer, 55:1931 [1985]	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/617,067		
		Filing Date	7/10/2003		
		First Named Inventor	Beer et al.		
		Art Unit	1643		
		Examiner Name	Sang		
Sheet	3	of	5	Attorney Docket Number	UM-08196

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	21	Hibi et al., "PGP9.5 as a candidate tumor marker for non-small-cell lung cancer," Am. J. Pathol., 155:711 [1999]	
	22	Brichory et al., "Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer," Cancer Res., 61:7908 [2001]	
	23	Koivunen et al., "Structures of the human gene for the protein disulfide isomerase-related polypeptide ERp60 and a processed gene and assignment of these genes to 15q15 and 1q21," Genomics, 42:397 [1997]	
	24	Hirano et al., "Molecular cloning of the human glucose-regulated protein ERp57/GRP58, a thiol-dependent reductase. Identification of its secretory form and inducible expression by the oncogenic transformation," Eur. J. Biochem., 234:336 [1995]	
	25	Montgomerie et al., "The 28K protein in urinary bladder, squamous metaplasia and urine is triosephosphate isomerase," Clin. Biochem., 30:613 [1997]	
	26	Tew et al., "Glutathione-associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program," Mol. Pharmacol. 50:149 [1996]	
	27	Nakamura et al., "Dynamics of bovine glial fibrillary acidic protein phosphorylation," Neurosci Lett 205:91 [1996]	
	28	Giasson et al., "Intermediate filament disassembly in cultured dorsal root ganglion neurons is associated with amino-terminal head domain phosphorylation of specific subunits," J Neurochem 70: 1869 [1998]	
	29	Escribano and Rozengurt, "Cyclic AMP increasing agents rapidly stimulate vimentin phosphorylation in quiescent cultures of Swiss 3T3 cells," J Cell Physiol 137: 223 [1988]	
	30	Eriksson et al., "Cytoskeletal integrity in interphase cells requires protein phosphatase activity," Proc Natl Acad Sci USA 89:11093 [1992]	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/617,067
		Filing Date	7/10/2003
		First Named Inventor	Beer et al.
		Art Unit	1643
		Examiner Name	Sang
		Attorney Docket Number	UM-08196
Sheet	4	of	5

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	31	Ku et al., "Identification of the major physiologic phosphorylation site of human keratin 18: potential kinases and a role in filament reorganization," J Cell Biol. 127:161 [1994]	
	32	MacFarlane et al., "Active caspases and cleaved cytokeratins are sequestered into cytoplasmic inclusions in TRAIL-induced apoptosis," J Cell Biol 148:1239 [2000]	
	33	Leers et al., "Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis," J Pathol. 187:567 [1999]	
	34	Spencer et al., "Estrogen regulates the association of intermediate filament proteins with nuclear DNA in human breast cancer cells," J Biol Chem 273:29093 [1998]	
	35	Hembrough et al., "Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation," Biochem J 317:763 [1996]	
	36	Fujita et al., "Detection of large molecular weight cytokeratin 8 as carrier protein of CA19-9 in non-small-cell lung cancer cell lines," Br J Cancer 81:769 [1999]	
	37	Takada et al., "Adhesion of human cancer cells to vascular endothelium mediated by a carbohydrate antigen, sialyl Lewis A.," Biochem Biophys Res Commun 179:713 [1991]	
	38	Takada et al., "Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium.," Cancer Res 53:354 [1993]	
	39	Pujol et al., "Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer," Cancer Res 53:61 [1993]	
	40	Pujol et al., "Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS," Am J Respir Crit Care Med 154:725 [1996]	

Examiner Signature	Date Considered	
--------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/617,067
		Filing Date	7/10/2003
		First Named Inventor	Beer et al.
		Art Unit	1643
		Examiner Name	Sang
Sheet	5	of	5
		Attorney Docket Number	UM-08196

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	41	Giordano et al., "Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles," Am. J. Pathol. 159:1231 [2001]	
	42	Hanash et al., "Data base analysis of protein expression patterns during T-cell ontogeny and activation," PNAS 90:3314 [1993]	
	43	Oh et al., "A database of protein expression in lung cancer," Proteomics 1:1303 [2001]	
	44	Moll et al., "The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells, Cell 31:11 [1982]	
	45	Glass et al., "Isolation, sequence, and differential expression of a human K7 gene in simple epithelial cells," J Cell Biol 107:1337 [1988]	
	46	Leube et al., "Cytokeratin expression in simple epithelia. III. Detection of mRNAs encoding human cytokeratins nos. 8 and 18 in normal and tumor cells by hybridization with cDNA sequences in vitro and in situ," Differentiation 33:69-85 [1986]	
	47	Broers et al., "Expression of intermediate filament proteins in fetal and adult human lung tissues," Differentiation 40:119 [1989]	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.